dabrafenib

Also known as DRB436, GSK2118436, GSK2118436A, Tafinlar®

Dabrafenib, sold under the brand name Tafinlar among others, is an anti-cancer medication used for the treatment of cancers associated with a mutated version of the gene BRAF. Dabrafenib acts as an inhibitor of the associated enzyme B-Raf, which plays a role in the regulation of cell growth.

Key facts

Drug.image: Dabrafenib.svg
Drug.image_class: skin-invert-image
Drug.image2: Dabrafenib-from-xtal-3D-bs-17.png
Drug.image_class2: bg-transparent
Drug.width: 200
Drug.tradename: Tafinlar
Drug.MedlinePlus: a613038
Drug.DailyMedID: Dabrafenib
Drug.routes_of_administration: By mouth
Drug.ATC_prefix: L01
Drug.ATC_suffix: EC02
Drug.legal_AU: S4
Drug.legal_CA: Rx-only
Drug.legal_US: Rx-only
Drug.legal_EU: Rx-only
Drug.legal_status: Rx-only
Drug.CAS_number: 1195765-45-7
Drug.PubChem: 44462760

via Wikipedia infobox

Chemical data

Formula: C23H20F3N5O2S2
Molecular weight: 519.6 g/mol
IUPAC name: N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide

via PubChem

Drug data · ChEMBL

Max clinical phase: Approved
Molecule type: Small molecule
First approval: 2013
Admin. routes: oral
Indications: neoplasm, melanoma, liver disease, brain neoplasm

via ChEMBL · EBI

Research

2,353 papers

Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.The New England journal of medicine · 2024
Dabrafenib.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2014
Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations.The New England journal of medicine · 2023
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.The New England journal of medicine · 2017
Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.The Lancet. Oncology · 2017

via PubMed

Wikidata facts

Mass: 519.101

Show 4 more facts

chemical formula: C₂₃H₂₀F₃N₅O₂S₂
canonical SMILES: CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F
World Health Organisation international non-proprietary name: dabrafenib
Commons category: Dabrafenib

Sources (6)

via Wikidata · CC0

~5 min read

Article

10 sections

Contents

Medical uses
History
Society and culture
Legal status
United States
European Union
Brand names
Research
References
Further reading

{{Infobox drug | image = Dabrafenib.svg | image_class = skin-invert-image | image2 = Dabrafenib-from-xtal-3D-bs-17.png | image_class2 = bg-transparent | width = 200 | alt = | alt2 = | caption =